Mayo Foundation for Medical Education and Research

George G Klee

George Vasmatzis

Farhad Kosari

Eric W Klee

Donald J Tindall

David Alan Ahlquist

Robert B Jenkins

Charles Y Young

S Keith Anderson

Charles Y F Young

Patrick C Roche

Paul J Limburg

Thomas M Kollmeyer

Tohru Nakagawa

Karla V Ballman

Eric J Bergstralh

Bruce W Morlan

This document provides methods and materials related to assessing male mammals (e.g., humans) with prostate cancer. For example, methods and materials for predicting (1) which patients, at the time of PSA reoccurrence, will later develop systemic disease, (2) which patients, at the time of retropubic radial prostatectomy, will later develop systemic disease, and (3) which patients, at the time of systemic disease, will later die from prostate cancer are provided.

Biomarker panels for predicting prostate cancer outcomes

This document relates to methods and materials involved in identifying, assessing, and monitoring prostate cancer in male mammals. For example, this document provides arrays for detecting polypeptides or nucleic acids that can be used to identify prostate cancer in male mammals. In addition, methods and materials for assessing and monitoring prostate cancer in mammals are provided herein.

Extracellular and membrane-associated prostate cancer markers

A method for calibrating a clinical laboratory analytical instrument that includes generating control pool data from a commutable control pool, wherein the control pools have target analyte values for an assay, generating patient specimen data from a distribution of test values from patient specimens, determining tolerance limits from the control pool data and the patient specimen data; and adjusting the calibration of the instrument with respect to the tolerance limits.

Clinical assay calibration adjustment method

Breast cancer is detected by determining the presence of hK2 polypeptide or hK2 RNA in a physiological sample.

Method for detection of breast cancer

A method of recovering colorectal epithelial cells or fragments thereof from a stool sample is provided. The method involves contacting a stool sample with a specific binding reagent having specificity for colorectal epithelial cells or membrane fragments thereof to form a complex containing the specific binding reagent and the colorectal epithelial cells or fragments thereof, and separating the complex from the sample. A method of detecting dysplastic colorectal epithelial cells or fragments thereof, wherein a specific binding reagent employed in the method has specificity for dysplastic colorectal epithelial cells or membrane fragments thereof, is also provided. An article of manufacture containing reagents for performing the method is further provided.

Methods of recovering colorectal epithelial cells or fragments thereof

The present invention provides an isolated preparation of monoclonal or polyclonal antibodies which react specifically with human prostate-specific glandular kallikrein (hK2), but which do not cross-react with human prostate-specific antigen (PSA), as well as immunogenic hK2 antigens useful to provide such antibodies.

Antibodies specific for human prostate glandular kallkrein

Growing community of inventors

Rochester, MN, United States of America

George G Klee